Entvin AI, a startup established by three graduates from IIT Bombay, has officially launched after its beta phase and announced it has secured $500,000 in its initial funding round from Y Combinator. The company specializes in providing AI solutions tailored for pharmaceutical and life sciences firms globally and aims to enhance its AI capabilities while accelerating customer acquisition among mid-to-large pharmaceutical companies worldwide.
The founders of Entvin AI are Sanskar Jain, Hemant Phalak, and Rishabh Arya. They have created an AI platform designed to simplify the complex, time-consuming, and resource-heavy FDA drug approval process. The startup has reported early success with enterprise pilot customers, showcasing that its AI solution can save regulatory and scientific teams hundreds of hours while enhancing compliance accuracy—an essential aspect in an industry where regulatory errors can lead to significant financial losses.
Given that the FDA drug approval process can take years and incur millions in costs, any inefficiencies can greatly affect a company’s profitability and delay critical treatments from reaching patients. Entvin AI seeks to address this challenge with a platform specifically designed for regulatory teams.
The startup’s platform targets this bottleneck by automating tasks such as document drafting, compliance verification, and regulatory monitoring, which typically require thousands of hours of skilled labor. Its technical framework utilizes large language models that are finely tuned for regulatory documentation and FDA compliance standards.
Sanskar Jain, Co-Founder & CEO of Entvin, said, “We identified a significant opportunity to transform how life sciences companies navigate regulatory requirements. Regulatory professionals spend countless hours on documentation, compliance checks, and staying updated with constantly evolving FDA guidelines. Our AI agents streamline these workflows, allowing teams to focus on strategic priorities rather than administrative burdens.”
Hemant Phalak, Co-Founder & CPO, said, “At Entvin, our AI agents seamlessly integrate into existing workflows to enhance efficiency and accelerate decision-making. Our platform doesn’t just organize information – it actively identifies compliance gaps, automates repetitive documentation tasks, and provides regulatory teams with actionable insights in real time. This helps life science companies navigate the approval process with unprecedented efficiency while maintaining trust, reliability and seamless integration.”
Rishabh Arya, Co-Founder & CTO of Entvin, said, “We’ve developed an AI system that deeply understands the complex language of FDA regulations and can process massive volumes of regulatory documentation. Our architecture is enterprise-grade, designed to meet the highest compliance standards required by pharmaceutical companies like SOC 2, ISO 2700.”
Also read: Viksit Workforce for a Viksit Bharat
Do Follow: The Mainstream formerly known as CIO News LinkedIn Account | The Mainstream formerly known as CIO News Facebook | The Mainstream formerly known as CIO News Youtube | The Mainstream formerly known as CIO News Twitter |The Mainstream formerly known as CIO News Whatsapp Channel | The Mainstream formerly known as CIO News Instagram
About us:
The Mainstream formerly known as CIO News is a premier platform dedicated to delivering latest news, updates, and insights from the tech industry. With its strong foundation of intellectual property and thought leadership, the platform is well-positioned to stay ahead of the curve and lead conversations about how technology shapes our world. From its early days as CIO News to its rebranding as The Mainstream on November 28, 2024, it has been expanding its global reach, targeting key markets in the Middle East & Africa, ASEAN, the USA, and the UK. The Mainstream is a vision to put technology at the center of every conversation, inspiring professionals and organizations to embrace the future of tech.
